Back to today’s briefing

Story perspectives

CEL-SCI's Multikine Boosts Survival in Cancer Treatment

5/15/2025

22 1

Summary

Story summary

CEL-SCI Corporation, a Virginia-based pioneer in cancer treatment, is making waves with its groundbreaking neoadjuvant immunotherapy, Multikine. Designed to boost the immune system before conventional therapies, Multikine is showing encouraging results in enhancing survival and quality of life for head and neck cancer patients. With FDA approval for a confirmatory study, the future looks bright for this innovative approach.

1 of 1

Story summary

CEL-SCI Corporation, a Virginia-based pioneer in cancer treatment, is making waves with its groundbreaking neoadjuvant immunotherapy, Multikine. Designed to boost the immune system before conventional therapies, Multikine is showing encouraging results in enhancing survival and quality of life for head and neck cancer patients. With FDA approval for a confirmatory study, the future looks bright for this innovative approach.